Search

Your search keyword '"Heerspink, Hiddo J.L."' showing total 19 results
Start Over Author "Heerspink, Hiddo J.L." Journal diabetes care
19 results on '"Heerspink, Hiddo J.L."'

2. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis

Author

Heerspink, Hiddo J.L., primary, Sattar, Naveed, additional, Pavo, Imre, additional, Haupt, Axel, additional, Duffin, Kevin L., additional, Yang, Zhengyu, additional, Wiese, Russell J., additional, Wilson, Jonathan M., additional, Hemmingway, Andrea, additional, Cherney, David Z.I., additional, and Tuttle, Katherine R., additional

Published
2023
Full Text
View/download PDF

4. Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Author

Heerspink, Hiddo J.L., primary, Apperloo, Ellen, additional, Davies, Melanie, additional, Dicker, Dror, additional, Kandler, Kristian, additional, Rosenstock, Julio, additional, Sørrig, Rasmus, additional, Lawson, Jack, additional, Zeuthen, Niels, additional, and Cherney, David, additional

Published
2023
Full Text
View/download PDF

5. Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Author

Beernink, Jelle M., primary, Persson, Frederik, additional, Jongs, Niels, additional, Laverman, Gozewijn D., additional, Chertow, Glenn M., additional, McMurray, John J.V., additional, Langkilde, Anna Maria, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Sjöström, C. David, additional, Toto, Robert D., additional, Wheeler, David C., additional, and Heerspink, Hiddo J.L., additional

Published
2023
Full Text
View/download PDF

6. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial

Author

Curovic, Viktor Rotbain, primary, Jongs, Niels, additional, Kroonen, Marjolein Y.A.M., additional, Zobel, Emilie H., additional, Hansen, Tine W., additional, Sen, Taha, additional, Laverman, Gozewijn D., additional, Kooy, Adriaan, additional, Persson, Frederik, additional, Rossing, Peter, additional, and Heerspink, Hiddo J.L., additional

Published
2023
Full Text
View/download PDF

7. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Author

Koshino, Akihiko, primary, Schechter, Meir, additional, Sen, Taha, additional, Vart, Priya, additional, Neuen, Brendon L., additional, Neal, Bruce, additional, Arnott, Clare, additional, Perkovic, Vlado, additional, Ridker, Paul M., additional, Tuttle, Katherine R., additional, Hansen, Michael K., additional, and Heerspink, Hiddo J.L., additional

Published
2022
Full Text
View/download PDF

8. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Author

Mosenzon, Ofri, primary, Raz, Itamar, additional, Wiviott, Stephen D., additional, Schechter, Meir, additional, Goodrich, Erica L., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Murphy, Sabina A., additional, Zelniker, Thomas A., additional, Langkilde, Anna Maria, additional, Gause-Nilsson, Ingrid A.M., additional, Fredriksson, Martin, additional, Johansson, Peter A., additional, Wilding, John P.H., additional, McGuire, Darren K., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, Cahn, Avivit, additional, Dwyer, Jamie P., additional, Heerspink, Hiddo J.L., additional, and Sabatine, Marc S., additional

Published
2022
Full Text
View/download PDF

9. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database

Author

Nagasu, Hajime, primary, Yano, Yuichiro, additional, Kanegae, Hiroshi, additional, Heerspink, Hiddo J.L., additional, Nangaku, Masaomi, additional, Hirakawa, Yosuke, additional, Sugawara, Yuka, additional, Nakagawa, Naoki, additional, Tani, Yuji, additional, Wada, Jun, additional, Sugiyama, Hitoshi, additional, Tsuruya, Kazuhiko, additional, Nakano, Toshiaki, additional, Maruyama, Shoichi, additional, Wada, Takashi, additional, Yamagata, Kunihiro, additional, Narita, Ichiei, additional, Tamura, Kouichi, additional, Yanagita, Motoko, additional, Terada, Yoshio, additional, Shigematsu, Takashi, additional, Sofue, Tadashi, additional, Ito, Takafumi, additional, Okada, Hirokazu, additional, Nakashima, Naoki, additional, Kataoka, Hiromi, additional, Ohe, Kazuhiko, additional, Okada, Mihoko, additional, Itano, Seiji, additional, Nishiyama, Akira, additional, Kanda, Eiichiro, additional, Ueki, Kohjiro, additional, and Kashihara, Naoki, additional

Published
2021
Full Text
View/download PDF

10. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Author

Mosenzon, Ofri, primary, Wiviott, Stephen D., additional, Heerspink, Hiddo J.L., additional, Dwyer, Jamie P., additional, Cahn, Avivit, additional, Goodrich, Erica L., additional, Rozenberg, Aliza, additional, Schechter, Meir, additional, Yanuv, Ilan, additional, Murphy, Sabina A., additional, Zelniker, Thomas A., additional, Gause-Nilsson, Ingrid A.M., additional, Langkilde, Anna Maria, additional, Fredriksson, Martin, additional, Johansson, Peter A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P.H., additional, Sabatine, Marc S., additional, and Raz, Itamar, additional

Published
2021
Full Text
View/download PDF

11. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes.

Author

Grams, Morgan E., Brunskill, Nigel J., Ballew, Shoshana H., Sang, Yingying, Coresh, Josef, Matsushita, Kunihiro, Surapaneni, Aditya, Bell, Samira, Carrero, Juan J., Chodick, Gabriel, Evans, Marie, Heerspink, Hiddo J.L., Inker, Lesley A., Iseki, Kunitoshi, Kalra, Philip A., Kirchner, H. Lester, Lee, Brian J., Levin, Adeera, Major, Rupert W., and Medcalf, James

Subjects
CHRONIC kidney failure, GLOMERULAR filtration rate, RESEARCH, KIDNEYS, META-analysis, KIDNEY failure, RESEARCH methodology, DIABETES, EVALUATION research, COMPARATIVE studies, RESEARCH funding, ALBUMINURIA
Abstract

Objective: To predict adverse kidney outcomes for use in optimizing medical management and clinical trial design.Research Design and Methods: In this meta-analysis of individual participant data, 43 cohorts (N = 1,621,817) from research studies, electronic medical records, and clinical trials with global representation were separated into development and validation cohorts. Models were developed and validated within strata of diabetes mellitus (presence or absence) and estimated glomerular filtration rate (eGFR; ≥60 or <60 mL/min/1.73 m2) to predict a composite of ≥40% decline in eGFR or kidney failure (i.e., receipt of kidney replacement therapy) over 2-3 years.Results: There were 17,399 and 24,591 events in development and validation cohorts, respectively. Models predicting ≥40% eGFR decline or kidney failure incorporated age, sex, eGFR, albuminuria, systolic blood pressure, antihypertensive medication use, history of heart failure, coronary heart disease, atrial fibrillation, smoking status, and BMI, and, in those with diabetes, hemoglobin A1c, insulin use, and oral diabetes medication use. The median C-statistic was 0.774 (interquartile range [IQR] = 0.753, 0.782) in the diabetes and higher-eGFR validation cohorts; 0.769 (IQR = 0.758, 0.808) in the diabetes and lower-eGFR validation cohorts; 0.740 (IQR = 0.717, 0.763) in the no diabetes and higher-eGFR validation cohorts; and 0.750 (IQR = 0.731, 0.785) in the no diabetes and lower-eGFR validation cohorts. Incorporating the previous 2-year eGFR slope minimally improved model performance, and then only in the higher-eGFR cohorts.Conclusions: Novel prediction equations for a decline of ≥40% in eGFR can be applied successfully for use in the general population in persons with and without diabetes with higher or lower eGFR. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Author

Persson, Frederik, primary, Rossing, Peter, additional, Vart, Priya, additional, Chertow, Glenn M., additional, Hou, Fan Fan, additional, Jongs, Niels, additional, McMurray, John J.V., additional, Correa-Rotter, Ricardo, additional, Bajaj, Harpreet S., additional, Stefansson, Bergur V., additional, Toto, Robert D., additional, Langkilde, Anna Maria, additional, Wheeler, David C., additional, and Heerspink, Hiddo J.L., additional

Published
2021
Full Text
View/download PDF

13. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

Author

Persson, Frederik, primary, Bain, Stephen C., additional, Mosenzon, Ofri, additional, Heerspink, Hiddo J.L., additional, Mann, Johannes F.E., additional, Pratley, Richard, additional, Raz, Itamar, additional, Idorn, Thomas, additional, Rasmussen, Søren, additional, von Scholten, Bernt Johan, additional, and Rossing, Peter, additional

Published
2021
Full Text
View/download PDF

14. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Author

Scholtes, Rosalie A., primary, Muskiet, Marcel H.A., additional, van Baar, Michiel J.B., additional, Hesp, Anne C., additional, Greasley, Peter J., additional, Karlsson, Cecilia, additional, Hammarstedt, Ann, additional, Arya, Niki, additional, van Raalte, Daniël H., additional, and Heerspink, Hiddo J.L., additional

Published
2020
Full Text
View/download PDF

16. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL

Author

Clegg, Lindsay E., primary, Heerspink, Hiddo J.L., additional, Penland, Robert C., additional, Tang, Weifeng, additional, Boulton, David W., additional, Bachina, Srinivas, additional, Fox, Robert D., additional, Fenici, Peter, additional, Thuresson, Marcus, additional, Mentz, Robert J., additional, Hernandez, Adrian F., additional, and Holman, Rury R., additional

Published
2018
Full Text
View/download PDF

17. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.

Author

Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Karlsson, Cecilia, Hammarstedt, Ann, Arya, Niki, van Raalte, Daniël H., and Heerspink, Hiddo J.L.

Subjects
DAPAGLIFLOZIN, KIDNEY physiology, TYPE 2 diabetes, BLOOD volume, SYSTOLIC blood pressure, SODIUM-glucose cotransporter 2 inhibitors
Abstract

Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for heart failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and plasma volume contraction. Few studies have investigated this hypothesis, but none have assessed cumulative sodium excretion with SGLT2 inhibition during standardized sodium intake in patients with type 2 diabetes.Research Design and Methods: The DAPASALT trial was a mechanistic, nonrandomized, open-label study in patients with type 2 diabetes with preserved kidney function on a controlled standardized sodium diet (150 mmol/day). It evaluated the effects of dapagliflozin on sodium excretion, 24-h blood pressure, and extracellular, intracellular, and plasma volumes at the start of treatment (ST) (days 2-4), end of treatment (ET) (days 12-14), and follow-up (FU) (days 15-18).Results: Fourteen patients were included in the efficacy analysis. Mean (SD) baseline sodium excretion (150 [32] mmol/24-h) did not significantly change during treatment (change at ST: -7.0 mmol/24-h [95% CI -22.4, 8.4]; change at ET: 2.1 mmol/24-h [-28.8, 33.0]). Mean baseline 24-h systolic blood pressure was 128 (10) mmHg and significantly reduced at ST (-6.1 mmHg [-9.1, -3.1]; P < 0.001) and ET (-7.2 mmHg [-10.0, -4.3]; P < 0.001). Dapagliflozin did not significantly alter plasma volume or intracellular volume, while extracellular volume changed at ST (-0.7 L [-1.3, -0.1]; P = 0.02). As expected, 24-h urinary glucose excretion significantly increased during dapagliflozin treatment and reversed during FU.Conclusions: During standardized sodium intake, dapagliflozin reduced blood pressure without clear changes in urinary sodium excretion, suggesting that factors other than natriuresis and volume changes may contribute to the blood pressure-lowering effects. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes

Author

Mayer, Gert, primary, Heerspink, Hiddo J.L., additional, Aschauer, Constantin, additional, Heinzel, Andreas, additional, Heinze, Georg, additional, Kainz, Alexander, additional, Sunzenauer, Judith, additional, Perco, Paul, additional, de Zeeuw, Dick, additional, Rossing, Peter, additional, Pena, Michelle, additional, and Oberbauer, Rainer, additional

Published
2017
Full Text
View/download PDF

19. Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography–Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes

Author

de Boer, Stefanie A., primary, Hovinga-de Boer, Marieke C., additional, Heerspink, Hiddo J.L., additional, Lefrandt, Joop D., additional, van Roon, Arie M., additional, Lutgers, Helen L., additional, Glaudemans, Andor W.J.M., additional, Kamphuisen, Pieter W., additional, Slart, Riemer H.J.A., additional, and Mulder, Douwe J., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results